Trials / Completed
CompletedNCT03071510
Evaluation of the Atlas Genetics io® CTNG System
IO-CTNG: A Multi-Centre Evaluation of the Atlas Genetics io® CTNG System Used in Centralised and Point of Care Settings
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 7,128 (actual)
- Sponsor
- Binx Health Limited · Industry
- Sex
- All
- Age
- 14 Years
- Healthy volunteers
- Accepted
Summary
Atlas Genetics io® system results are compared with those obtained from comparator devices.
Detailed description
Results from the Atlas Genetics io® system are compared with a Composite Infection Status obtained from testing on three commonly used comparator devices. This is a prospective, single-arm, multi-centre investigation enrolling up to 12,000 adult participants over 14 years of age who are undergoing testing for the presence of CT/NG.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Atlas Genetics io® system | Specimen Collection |
Timeline
- Start date
- 2017-05-18
- Primary completion
- 2019-08-30
- Completion
- 2019-08-30
- First posted
- 2017-03-07
- Last updated
- 2020-04-03
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03071510. Inclusion in this directory is not an endorsement.